Logo Image
|Videos|July 20, 2016

What Can Healthcare Providers do to Help Stop HAIs?

Marion A. Kainer, MD, MPH, FRACP, FSHEA, provides key points to help healthcare providers prevent healthcare associated infections.

Marion A. Kainer, MD, MPH, FRACP, FSHEA, provides key points to help healthcare providers prevent healthcare associated infections.

Interview Transcript (slightly modified for readability)

“Well, [healthcare providers should try to] prevent infection in the first place. So that is, adhering to particular bundles, such as the central line insertion bundle. [We should also be] making sure that we insert tubes cleanly and safely; making sure that we wash our hands; making sure that we wear the appropriate protective equipment, gloves and gowns, when needed; vaccinating our healthcare workers; making sure our patients are vaccinated; and [paying] attention to antimicrobial stewardship, [by] using antibiotics wisely.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more